750 studies found for:    "Hypercholesterolemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Hypercholesterolemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
2 Completed
Has Results
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
3 Completed
Has Results
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
4 Completed Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.
Conditions: Familial Hypercholesterolemias;   Weight Loss;   Familial Combined Hypercholesterolemia;   Obesity
Intervention: Behavioral: Weight loss and dietary intervention
5 Terminated
Has Results
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Conditions: Hypercholesterolemia, Familial;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: MK-0524A
6 Completed Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Condition: Hypercholesterolemia
Intervention:
7 Completed A Study to Evaluate the Effects of MK0653 on the Postprandial (Following a Meal) Lipoprotein Response in Patients With Primary Hypercholesterolemia (High Cholesterol)
Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe;   Drug: Comparator: placebo
8 Completed A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions: Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
9 Completed A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions: Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
10 Recruiting Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: alirocumab SAR236553 (REGN727);   Drug: pravastatin;   Drug: simvastatin;   Drug: fluvastatin;   Drug: atorvastatin;   Drug: pitavastatin;   Drug: rosuvastatin
11 Completed Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
12 Completed
Has Results
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
Conditions: Primary Hypercholesterolemia;   Homozygous Familial Hypercholesterolemia
Intervention: Drug: Ezetimibe
13 Completed Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention: Drug: MD-0727
14 Withdrawn Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Interventions: Biological: Placebo;   Biological: 1 mg/kg every 2 weeks;   Biological: 2 mg/kg every 4 weeks;   Biological: 4 mg/kg every 4 weeks;   Biological: 4 mg/kg every 8 weeks;   Biological: 8 mg/kg every 8 weeks;   Biological: 12 mg/kg every 8 weeks
15 Completed Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Biological: PF-04950615 (RN316)
16 Recruiting Study of Awareness and Detection of Familial Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
17 Completed Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Cardiovascular Disease;   Hypertension;   Diabetes;   Coronary Heart Disease;   Peripheral Arterial Disease
Intervention:
18 Completed Pan-European Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
19 Completed Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
20 Completed
Has Results
Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Drug: Pitavastatin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years